2. United Therapeutics Corporation (NASDAQ:UTHR)
United Therapeutics is one of the more specialized biotech stocks on this list because its story is heavily tied to serious cardiopulmonary and respiratory diseases. That may sound narrow at first, but it is exactly what gives the company its strength. In biotech, focused companies can become highly valuable when they dominate difficult disease categories with real unmet need. United Therapeutics has built its business around therapies for pulmonary arterial hypertension and related conditions, and investors are now watching whether its clinical programs can expand that opportunity further.
The May 2026 watchlist described United Therapeutics as a company developing and commercializing products for chronic and life-threatening diseases, including Tyvaso DPI, Tyvaso inhaled solution, Remodulin, Orenitram, and Adcirca. These treatments are used in pulmonary arterial hypertension and related conditions where patients often require long-term and specialized therapy. That makes the company’s revenue base more medically focused than many broader healthcare names.
The latest quarterly data showed a mixed but still important story. United Therapeutics reported first-quarter 2026 total revenue of $781.5 million, down 2% from $794.4 million in the first quarter of 2025. Net income was $274.9 million, down 15%, while diluted EPS was $5.82, down 12% year over year. Total Tyvaso revenue decreased 2% to $457.5 million, but Tyvaso DPI revenue increased 9% to $330.3 million, partly offsetting the decline in nebulized Tyvaso revenue. Orenitram revenue also grew 12% to $135.6 million.
CEO Martine Rothblatt gave the key strategic message, saying, “In the first quarter of 2026, we extended our run of clinical success,” pointing to positive results from both the ADVANCE OUTCOMES and TETON-1 studies. She added that these readouts have the potential to meaningfully expand future growth and support further revenue diversification, while reinforcing the company’s long-term commitment to patients with serious cardiopulmonary and respiratory disease. That is a strong statement because it shifts the narrative away from the slight revenue decline and toward future label expansion and clinical progress.
President and COO Michael Benkowitz also addressed the commercial side directly, saying that although the competitive landscape for inhaled prostacyclins remains dynamic, continued growth for Tyvaso DPI reflects the resilience of the company’s commercial strategy. He said the company remains committed to returning to sequential quarterly revenue growth across the commercial portfolio in the near term. That matters because investors want to see not only clinical wins but also stronger commercial execution.
For investors searching for biotech stocks to watch now, pulmonary arterial hypertension stocks, respiratory disease biotech stocks, and high-conviction healthcare stocks, United Therapeutics remains compelling because it combines profitability, specialized disease leadership, and potential clinical expansion. The risk is that its revenue mix still depends heavily on Tyvaso, and competition in inhaled prostacyclins can pressure growth. Still, positive clinical readouts could help reshape the long-term story if they lead to broader use and future revenue diversification.
Click next to see the following stock...
